Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Emerg Drugs. 2008 Sep;13(3):417-30. doi: 10.1517/14728214.13.3.417 .

The development of the direct renin inhibitor aliskiren: treating hypertension and beyond.

Author information

  • 1University of Virginia, Charlottesville, VA 22908, USA. hms7a@virginia.edu

Abstract

BACKGROUND:

Direct renin inhibitors such as aliskiren offer a novel way of treating hypertension and its co-morbidities, conditions with a considerable prevalence, morbidity, and mortality worldwide.

OBJECTIVE:

The burden of hypertension worldwide and the role of the renin-angiotensin-aldosterone system in this disease will be reviewed. Current treatments for hypertension and its co-morbidities that work by manipulating this system will be discussed. The development of, and clinical trials involving, direct renin inhibitors will be reviewed, with a focus on aliskiren.

METHODS:

PubMed was utilized to search the most recent literature on the topics of the renin-angiotensin-aldosterone system, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosterone and aliskiren.

RESULTS/CONCLUSIONS:

The direct renin inhibitors, including aliskiren, are new agents with great promise for the treatment of hypertension and its co-morbid conditions, including renal and cardiovascular disease.

PMID:
18764720
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk